Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q34989774

about

Angiogenesis-inhibitors for metastatic thyroid cancer Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Cabozantinib for progressive metastatic medullary thyroid cancer: a review Medical management of metastatic medullary thyroid cancer Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.Update: the status of clinical trials with kinase inhibitors in thyroid cancer Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma.Vandetanib.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers Cabozantinib in progressive medullary thyroid cancer.Update on thyroid cancer treatment.Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Endocrine side effects of broad-acting kinase inhibitors.Biomarkers for anti-angiogenic therapy in cancer.Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.Thyroid cancer: emerging role for targeted therapies.Targeted treatment of differentiated and medullary thyroid cancer.Activated RET and ROS: two new driver mutations in lung adenocarcinoma.Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.New therapies for dedifferentiated papillary thyroid cancer Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.

P2860

Q24236743-1A5927D5-33AD-4BC0-BF54-7A2C57B705AD Q26764899-7F788429-A7D5-4D94-8B4B-67E43C99F7F3 Q26821959-7C79D1F9-4DCB-4289-B539-2415249BDCD1 Q26828884-1741E465-39CC-4959-928E-07EE273C9A40 Q26851709-A144D8C0-9D85-4A0C-A2A9-0D79ED17CCA2 Q27005897-6D97F2C1-CCC7-4599-A4C7-0A907033F6CE Q27851560-6F7A4752-2E74-4D76-8437-0B9BB10E5E67 Q28072655-D77EDB8B-48AB-49B1-94DC-64A0C2183069 Q28649731-4A63F407-0D38-4908-A9C2-78F1BA9C43FB Q30414010-B403ED3E-3B4C-4BBD-9CF2-A38914E72E65 Q33569049-A7862825-58C7-44E8-B041-3CCC1FF73C82 Q33570056-84650584-C973-4FF2-9A05-02242E56856C Q33587821-CE6F4748-9AD1-47E0-A5B7-2B762EDF4078 Q33710562-16123C89-0C4C-40D6-A748-6DB0428D0390 Q33727633-E3C74F11-161D-4A44-8799-E6BFCD3BAB30 Q33760079-C5D7B1EF-300D-4F0C-A6A7-9F03A04663E6 Q33813776-16E90B6C-3CF6-45E6-8580-5698B1B11319 Q33885538-9B37FAA1-F747-4743-9632-A0F9D7E2AF08 Q33984845-3EE6DDC3-A129-4313-B3BD-6F6471F6BC89 Q34031293-A197ECBF-370E-4B70-8919-F6A7415841B2 Q34046157-04B23724-594D-4CB9-A84E-CF27F0DDB43E Q34088265-01E0B57C-2EEB-435C-B7A4-A1CE0FC89DE6 Q34123724-C6799766-9DBB-409B-B000-C87F8DEB7EE7 Q34185084-7646767D-87DD-4BDB-9903-2AF296C1BA1D Q34310219-2D027436-3E6E-4A35-8D69-527EC79AE803 Q34337865-BB8285B2-CF31-43D6-AAAC-5873F6B679E3 Q34468665-8B3777FD-4DDE-4B18-82B8-ADC6A538DAEE Q34538390-FD6EBC0E-3E80-4AB1-95E2-2892621ACE1B Q34574985-6A473AD5-93EF-4F3F-99CF-511ACE2D0FCC Q34695003-74FBA0AE-DE0D-43B7-BEDD-5AB502F1E346 Q34714310-119C0160-F32B-4D49-8288-05B81B8B2814 Q34725749-0528D040-F716-4653-ACB7-77645EAB98CB Q34758477-3D5426AC-350E-4AE9-AAF6-29B12FCC38FF Q34923902-F45F6EF3-4603-40E7-8925-D2D166CE5DDA Q35076227-45ADAEA9-5474-48DC-985E-D0659139ABF3 Q35147151-ACB45F46-58A1-4414-866D-0A6DCE8B0E18 Q35206630-0ABB4E4B-F8F9-4924-ACFA-F0851A5DA89D Q35370655-452A4A58-D3E8-4D47-9551-0E77EB89692E Q35381593-885D0CC0-1324-4866-89CC-708BE07309B0 Q35396089-82871A55-29F4-4FE0-BBE0-9F63BF7F1AA4

P2860

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

http://www.wikidata.org/entity/Q34989774

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of safety and e ...... atic medullary thyroid cancer.

@ast

Phase II study of safety and e ...... atic medullary thyroid cancer.

@en

Phase II study of safety and e ...... atic medullary thyroid cancer.

@nl

type

label

Phase II study of safety and e ...... atic medullary thyroid cancer.

@ast

Phase II study of safety and e ...... atic medullary thyroid cancer.

@en

Phase II study of safety and e ...... atic medullary thyroid cancer.

@nl

prefLabel

Phase II study of safety and e ...... atic medullary thyroid cancer.

@ast

Phase II study of safety and e ...... atic medullary thyroid cancer.

@en

Phase II study of safety and e ...... atic medullary thyroid cancer.

@nl

P1433

Q34989774-72F6EDEB-017D-4328-96E4-8ADCADBF7AE3

P1476

Q34989774-4C42380B-8077-4051-9692-427EA45A59A3

P2093

Q34989774-039485E8-99E2-4710-90E9-87C375F58942

Q34989774-49DBFBAD-CE21-4EBD-BD0F-357CA0FB19AC

Q34989774-7F3DEF73-71E9-43DA-B4FF-E5346950C3A4

Q34989774-8220A596-42DE-4F47-9078-DDD43CA0023E

Q34989774-8AE640FF-434D-47CD-8C0E-E4FDEBFBB54B

Q34989774-A3B2F60D-0877-4A37-9A50-03CADAA7C943

Q34989774-A4FA9296-1258-49D4-9FC2-1E1422D0A169

Q34989774-C1DCAAFA-17F8-4285-AF21-3B59DF06BCDF

Q34989774-D40AA739-E68D-4B0B-BAED-F376CE0AFC8E

Q34989774-F42B51C8-BEF4-47C5-A773-28DB56EC7C45

P304

Q34989774-AE85542E-82DD-4860-B776-FA97F0F70F6A

P31

Q34989774-9B4B16F4-AC8E-4F8D-B4B3-246B7B5BDC55

P356

Q34989774-D2CD637F-92D5-4FD1-AD71-6A391429C4DF

P407

Q34989774-EB5E02B0-B70C-4892-8FB6-8BAF0845B9F6

P433

Q34989774-66817A02-AE12-4ABB-A7CD-372A10FC9EF5

P478

Q34989774-1BA9967B-EAC0-4E33-892E-A38AC0E5B800

P50

Q34989774-4A35CB2B-8F7A-4C6C-AA75-3BEAD9961EDC

Q34989774-7FC2AE3C-91CD-4129-A5E6-DF3697F4F126

Q34989774-B2864813-ED5E-4528-88F1-AEF92AC92006

Q34989774-B5350AC2-0125-4737-ABD1-C77F447C8BD5

Q34989774-C66660ED-A4A1-409B-9188-2438C6AB665A

P577

Q34989774-4A53D692-76E7-47F1-9C2A-D48373B62A5E

P698

Q34989774-1B6FB7B2-ECC3-412E-873E-AE248D1608A5

P921

Q34989774-D35AE5CA-D59C-4B21-B0B7-1A4F67F196A1

P356

JCO.2008.18.7815

P1433

Journal of Clinical Oncology

P1476

Phase II study of safety and e ...... tatic medullary thyroid cancer

@en

P2093

Chantal Daumerie

http://www.w3.org/2001/XMLSchema#string

Daniel E Stepan

http://www.w3.org/2001/XMLSchema#string

Furio Pacini

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Droz

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Martin J Schlumberger

http://www.w3.org/2001/XMLSchema#string

Michael J Eschenberg

http://www.w3.org/2001/XMLSchema#string

Renato G Martins

http://www.w3.org/2001/XMLSchema#string

Todd Juan

http://www.w3.org/2001/XMLSchema#string

Yu-Nien Sun

http://www.w3.org/2001/XMLSchema#string

P304

3794-3801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.7815

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Jarząb

Laura D. Locati

Steven I. Sherman

Rossella Elisei

P577

2009-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19564535

http://www.w3.org/2001/XMLSchema#string

P921